DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Coverage details, prior authorization criteria, copay ranges, and appeal strategy for 2026. Verified May 1, 2026.
Heavy Medicare Advantage focus. Weight-loss GLP-1 indication blocked on most Humana Medicare plans (Part D exclusion). T2D + cardiovascular indication covered. Commercial plans follow stricter PA.
Humana requires the following before approving Zepbound:
Top denial patterns we see in 2026 based on appeal-claim data:
Medicare members: OSA-with-obesity is the ONLY weight-management pathway covered. Sleep study with AHI ≥15 is mandatory.
Humana member portal → Coverage Determination → standard 14-day, expedited 72h.
Zepbound (tirzepatide 5-15mg) carries the following FDA-approved indications. Off-label use is the #1 PA denial reason — ensure your prescribing diagnosis matches one of these.
Coverage details verified May 1, 2026 against Humana formulary documentation. Formulary changes happen quarterly — always verify against your specific plan before prescribing.